ArticleJournal of gynecologic oncology2025
Prevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021-2023.
Article in Journal of gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Human Papillomavirus Positivity and Genotype Distribution Among Korean Females: A Large-Scale Laboratory-Based Analysis.Journal of clinical medicine · 2026Article
- Prevalence of high-risk human papillomavirus types among women aged 30-49 years in the Chuy region, Kyrgyzstan.Infectious agents and cancer · 2026Article
- Epidemiology of high-risk HPV in Uzbekistan among 44,000 women - genotypes, risk profiles and screening needs in Uzbekistan.BMC infectious diseases · 2025Article
- COVID-19 pandemic disruptions drive decreases in HPV prevalence and shift genotype distribution in Western China.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveCervical cancer remains a significant global health concern. Extensive research has established a critical link between human papillomavirus (HPV) infection and the development of cervical cancer. As a result, high-risk HPV (Hr-HPV) testing has emerged as a promising screening method. This study aimed to retrospectively analyze the prevalence of Hr-HPV genotypes among women in three regions of Uzbekistan.
methodsBetween 2021 and 2023, the Research Institute of Virology of Uzbekistan and the Korea Foundation for International Healthcare conducted a comprehensive population-based study in Tashkent, Andijan, and Samarkand. The study targeted 43,921 women aged 20 and above, utilizing real-time polymerase chain reaction to investigate the prevalence of 12 Hr-HPV genotypes. The analysis included an examination of the distribution of these genotypes based on age, region, and various demographic factors.
resultsThe overall prevalence of Hr-HPV among women aged 20 and above in Uzbekistan was 7.4%. Regional variations were observed and Hr-HPV prevalence was higher in individuals in their 20s than in other age groups in all 3 regions (p<0.001). The proportion of HPV 16 and 18 was 32.5% and 6.4% in the single infections, 41.9% and 14.7% in the double infections, and 59.3% and 20.0% in the multiple infections. There were also significant differences in prevalence across demographic factors, such as marital status, parity, current smoking, and contraceptive method (p<0.005).
conclusionThe findings emphasize the importance of early screening and educational initiatives, particularly targeting young and co-infected women. This foundational data aims to improve women's health strategies in Uzbekistan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.